iüLabs

SoluSmart® Technology: Molecular taxis for effective nutritional supplements

1/1 Photos

Key project data

Target amount

1.0M EUR

Valuations

12.0M EUR

Potential Returns

7.7-11.43x

End Date

2026-07-30

Would AI invest?

52/100

100

Invest Now

AI-Generated Overview

This overview is generated using artificial intelligence based on information available on the platform’s project page and publicly accessible data. It is provided for informational purposes only and does not constitute investment advice, financial guidance, risk assessment, or project scoring. Platforms and project owners are not involved in the creation, review, or endorsement of this content.

AI project overview

Condensed summary based on project data

<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong>iüLabs GmbH — Crowdfunding Investor Memo</strong></span></span></p>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><em>Premium dietary supplements built on the patented SoluSmart® absorption technology.</em></span></span></p>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong>Sector: </strong>Consumer health / dietary supplements   ·   <strong>Stage: </strong>Early commercialization (seed)   ·   <strong>HQ: </strong>Berlin, Germany   ·   <strong>Raise: </strong>€150K threshold / €1.0M max</span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; width:227px">
<p style="text-align:center"><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">AI SCORE</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:397px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong>Why this score:</strong></span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; width:227px">
<p style="text-align:center"> </p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:397px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>A credible scientific founder (Dr. Wolfgang Brysch, ~30 years pharma/biotech, co-inventor of 26 patents per public sources) but the deck's “four companies, three sold” claim could not be independently verified.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; width:227px">
<p style="text-align:center"><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="font-size:28.0pt"><span style="color:black">52 / 100</span></span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:397px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Real product-market signal — the company reports 1,600+ units sold since Q1 2025, a &gt;40% repurchase rate and €384 CLV — but all traction figures are company-stated and unaudited.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; width:227px">
<p style="text-align:center"><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style='font-family:"Segoe UI Emoji",sans-serif'><span style="color:black">⚠️</span></span><span style="color:black"> Caution</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:397px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Issuer-set €12M pre-money sits at roughly 100x the ≈€116K of 2025 plan revenue, with no methodology or external benchmark disclosed.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; width:227px">
<p style="text-align:center"> </p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:397px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>The instrument is a deeply subordinated profit-participating loan (not equity): investors rank behind essentially all creditors, payments can be blocked before insolvency, and total loss is explicitly possible.</span></span></li>
</ul>
</td>
</tr>
<tr>
<td style="background-color:#faece7; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; width:227px">
<p style="text-align:center"> </p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:397px">
<ul>
<li><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>The 48–58% p.a. / 6.83–9.42x headline is a target contingent on the company hitting its own multi-year plan, not a fixed return.</span></span></li>
</ul>
</td>
</tr>
</tbody>
</table>
<p> </p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#e6f1fb; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:624px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><span style="color:black">ℹ️ <strong>This is not investment advice. </strong></span><span style="color:#000000">The purpose of this overview is to help potential investors preselect crowdfunding projects quickly without making a final investment decision.  Before investing, the final selected project should be reviewed in detail based on the information provided by the company on the respective crowdfunding platform. AI can make mistakes, so you need to double-check data.</span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>🏢 Company description</span></span></p>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>iüLabs GmbH is a Berlin-based dietary-supplement company (HRB 235105 B) founded in 2020 that develops and sells premium supplements built on its patented, exclusively in-licensed SoluSmart® absorption technology, which the company reports forms multilamellar vesicles at preparation to raise the bioavailability of bioactive plant compounds. It currently sells three products directly to consumers via its own webshops — iüVitalizer (cellular energy/fatigue), iüMove (joints/mobility) and iüProtect (immune support) — with a stated pipeline covering menopause, sleep and long COVID. The company reports market entry with iüVitalizer in Q1 2025 and over 1,600 units sold since, a repurchase rate above 40% and a €384 customer lifetime value, all achieved without paid advertising (company-stated, unaudited). The team is led by majority owner Dr. Wolfgang Brysch (CEO &amp; Chief Scientific Officer, 61.86% of shares), with a COO, a chief medical advisor and a UK marketing lead. The round is a profit-participating subordinated loan via FunderNation with a €150K threshold and €1.0M maximum, raising funds for marketing, larger production batches, team expansion and new product development. The issuer set its own €12M pre-money valuation; its most recent (31.12.2024) accounts show an equity-uncovered shortfall.</span></span></p>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>🎯 <span style="color:#000000">Potential returns</span></span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:127px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Target return</span></strong></span></span></p>
</td>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:127px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Time horizon</span></strong></span></span></p>
</td>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:204px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Target basis</span></strong></span></span></p>
</td>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:167px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">AI view on reaching this goal</span></strong></span></span></p>
</td>
</tr>
<tr>
<td style="border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:127px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong>🎯 6.83–9.42x</strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:127px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong>⏱ ~5.4 yrs</strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:204px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong>Company-provided</strong> — the platform/company states a 48–58% p.a. / 6.83–9.42x target with a defined success-, bonus- and exit-interest mechanism tied to the issuer's own plan.</span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:167px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Plausible only if the company approaches its own aggressive multi-year revenue plan; under neutral or negative scenarios the company states no success interest is paid and principal can be lost.</span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>📈 Path to target return</span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Company methodology</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Returns are not a fixed coupon. The investor's participation quota (per €100 lent) is applied to (a) the issuer's annual net profit as success interest, (b) a maturity company-value figure for the bonus interest, and (c) net proceeds on a sale of &gt;50% of shares/assets for exit interest. At maturity, company value is set either by the last financing round within 12 months or, absent one, by 300% of the issuer's most recent annual revenue (company-stated).</span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Comparable exits cited</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Not disclosed in provided materials.</span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Milestones expected</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Per the company's financial plan: revenue ≈€636K (2026 base case) rising to ≈€2.6M (2027), first positive EBIT in 2027, and ≈€31.7M revenue / €8.7M net profit by 2031 (base case). </span></span><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Use of proceeds: ~35% marketing &amp; sales staff, ~30% external marketing providers, ~30% production materials, ~5% liquidity reserve (company-stated).</span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>💶 Valuation</span></span></p>
<table cellspacing="0" class="Table" style="border-collapse:collapse; border:none; width:6.5in">
<tbody>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Pre-money valuation</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:1px solid #cccccc; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>€12.0M (issuer-set, before the campaign).</span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Post-money valuation</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Up to €13.0M at the €1.0M funding maximum (pre-money + amount raised).</span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Instrument</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Profit-participating subordinated loan (partiarisches Nachrangdarlehen) — debt, not equity. No shares are issued.</span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">How the valuation was set</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Methodology not disclosed in provided materials — the €12M figure is set by the issuer with no comparables or derivation shown.</span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">External benchmarks</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>€12M pre-money is roughly 100x the ≈€116K of 2025 plan revenue. No external comparable transaction or third-party valuation was provided; insufficient comparables for this sector and stage in the dossier.</span></span></p>
</td>
</tr>
<tr>
<td style="background-color:#f4f2ec; border-bottom:1px solid #cccccc; border-left:1px solid #cccccc; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:180px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'><strong><span style="color:black">Notable terms</span></strong></span></span></p>
</td>
<td style="border-bottom:1px solid #cccccc; border-left:none; border-right:1px solid #cccccc; border-top:none; vertical-align:top; width:444px">
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>Investors within 31 days of launch receive a ~12.5% valuation bonus (0.000870% participation per €100 vs 0.000769% later). Issuer bears ~15% of amounts raised in platform/pooling/marketing costs. If the €150K threshold is not met within 90 days, investors are repaid in full without interest.</span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>📜 Instrument &amp; investor terms</span></span></p>
<h2><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>What you own</span></span></h2>
<p><span style="font-size:10pt"><span style='font-family:"Times New Roman",serif'>You are not buying shares. The instrument is a profit-participating subordinated loan (partiarisches Nachrangdarlehen): you lend money to iüLabs and, in return, receive interest linked to the company's profit, value and any sale — but you become a creditor, not a shareholder. Because there is no equity, there is no share class and no shareholder vote: you cannot vote at shareholder meetings or directly influence company decisions, including a decision to sell. Each loan is a direct contract between you and the issuer; for collective matters such as a buy-out or sale negotiation, a pooling arrangement run by FunderNation Support UG provides a voting procedure among loan-holders. In short, your influence…</span></span></p>

See full overview

Ask question

Ask AI about this project

Beta